Objective: This study aims to determine: the safety and efficacy of risperidone on treatment naive first episode schizophrenia for first episode schizophrenia; and the social and occupational outcome of these patients. Methodology: This trial was an open clinical study using oral risperidone for 8 weeks, in treatment naive first episode schizophrenia in Malaysia. All first episode schizophrenic patients from 3 general hospitals in Northern Johor that fulfilled the entry criteria were included in this study. They were assessed by using PANNS, CGI, HoNos, AIMS and Adverse rating scale. They were seen at week 0, 1, 2, 4, and 8 weeks. In the first week, risperidone was given given at 1mg per day and subsequently adjusted by no more than 1mg per week up to maximum of 8mg/day. Results: During the 9 month trial, 44 patients were diagnosed to have first episode schizophrenia, but only consented to be in the study. Nine patients had to dropped out because they required parentheral antipsychotic treatment. Thirty-one patients completed this 8 week trial. Using 20% reduction of PANSS score, 27 patients (87.1%) improved at 8 weeks. Using 50% reduction of PANSS initial score and CGI-S score of 1 or 2, 16 patients (51.6%) improved at 8 weeks.Adverse effects were reported in 8 of the patients (25.8%). The mean dose required was 2.69 mg/day, with maximum dose of 8 mg/day. Conclusion: Risperidone is an effective and safe antipsychotic for first episode schizophrenia in Malaysia. The doses required are substantially less than usually needed for chronic schizophrenia.
Human ; Male ; Female ; Aged ; Middle Aged ; Adult ; Young Adult ; Adolescent ; SCHIZOPHRENIA ; RISPERIDONE ; CLINICAL TRIAL

The aim of this review was to provide an update on the current status of digital occlusal force measurement devices, as well as clinical and research applications in complete arch maximum occlusal force measurement. SCOPUS, ScienceDirect, and PubMed databases were used to conduct a literature search from January 2001 to January 2021. Identification and screening of literature were done independently according to published guidelines and selection criteria. The electronic searches turned up 394 articles, 16 of which met the inclusion and exclusion criteria and were selected for study analysis. All of these studies used T-scan and Dental Prescale digital occlusal analysis system with pressure-sensitive foils as occlusal force measurement devices. The devices showed a promising potential for identifying and comprehending maximum occlusal forces objectively. According to the current review, maximum occlusal force measured with digital occlusal force devices can be used as a prosthodontic adjunct to address issues that arise during the treatment of occlusal disorders, temporomandibular disorders, and complete dentures. It is also useful in predicting cognitive and functional decline in the elderly.